Higher Gradient Whole-Body MRI Scanner Gets FDA Nod
At an amplitude of 200 mT/m and a slew rate of 200 T/m/s, the gradients for the FDA-cleared MAGNETOM Cima.X are reportedly the strongest for currently available whole-body MRI scanners.
Offering a robust gradient system and a variety of workflow enhancements, the MAGNETOM Cima.X 3T whole-body magnetic resonance imaging (MRI) scanner has garnered 510(k) clearance from the Food and Drug Administration (FDA).
Siemens Healthineers, the manufacturer of the MAGNETOM Cima.X system, said the device features Gemini Gradients that have an amplitude of 200 millitesla per meter (mT/m) and a slew rate of 200 telsa per meter per second (T/m/s).
For imaging of patients with neurodegenerative diseases, the industry-leading gradient strength enhances the visibility of microstructures in the brain, according to Siemens Healthineers. The company noted that the MAGNETOM Cima.X system also features the artificial intelligence (AI)-powered Deep Resolve reconstruction technology, which can accelerate MRI brain scans by 70 percent.
The newly FDA-cleared, whole-body MAGNETOM Cima.X MRI system offers enhanced gradient strength that may facilitate improved visualization of brain microstructures as well as artificial intelligence (AI)-powered reconstruction technology that can accelerate MRI brain scans by 70 percent, according to Siemens Healthineers, the manufacturer of the system.
Another benefit of the whole-body MRI modality, according to Siemens Healthineers, is the capability to provide time-stamped physiological data through the system’s Physiologging feature, which enables clinicians to ascertain whether respiratory activity is compromising brain activity.
“With the FDA clearance of the MAGNETOM Cima.X, Siemens Healthineers proudly offers the scientific and medical communities a whole-body 3T MR scanner that can deliver penetrating new insights into oncologic, cardiac, and neurodegenerative disease,” noted Katie Grant, the vice president of magnetic resonance at Siemens Healthineers North America.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
